A Phase 2 interventional study of XEN1101 in Focal Epilepsy, sponsored by Xenon Pharmaceuticals Inc.. Active, not recruiting at 95 sites in 9 countries. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-11-05.
Sponsored by Xenon Pharmaceuticals Inc. · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 102 studies in Epilepsies, Partial with a site in United States — 18 open to participants now, 24 under way, 6 of them phase 3. Epilepsies, Partial · United States.
Among the 102 studies in Epilepsies, Partial with a site in United States, this one is the 17th largest by enrollment of the 86 interventional ones that give a count, is one of 2 that started in 2019, is one of 23 in phase 2, reaches primary completion later than 0 of the 22 other live ones, and was the 71st registered.
243 studies on the registry are indexed under Epilepsies, Partial; 49 are open to participants now.
Browse Epilepsies, Partial studies →18 of the 102 studies in Epilepsies, Partial with a site in United States are open now. Recruiting first, the newest first:
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States, Australia, Korea, Republic of and 1 more country
Ages 18–75
Mayo Clinic · Sites in United States
Ages 18–75
Rapport Therapeutics Inc. · Sites in United States
Ages 18–70
University of California, San Francisco · Sites in United States
Ages 21–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 37 Epilepsies, Partial studies recruiting now, 9 (24%) set no upper age limit and 24 (65%) stop at 75 or younger; 17 take children under 18; 3 take healthy volunteers.
This study: 18 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
102 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 6 · Phase 2 28 · Phase 3 34 · Phase 4 9
First in 1992; this study’s year is marked. 2 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 325 is above the median of 90 across 187 interventional studies indexed under Epilepsies, Partial.
Median enrollment 100 across the 86 interventional studies, 100 across the 16 observational. Of the 73 that completed or were terminated, 37 (51%) have results posted.
This tab as a report to print or save as PDF → With an account.
63 of 102 have an industry lead sponsor. The 10 most frequent:
Xenon Pharmaceuticals Inc. is the lead sponsor of 23 studies on the registry; 3 are open to participants now.
Xenon Pharmaceuticals Inc. has 2 studies filed under Epilepsies, Partial — fewer than ten, so there is no comparison to draw.
10 of the studies in Epilepsies, Partial with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06132893Phase 3Biohaven Therapeutics Ltd.A Study to Determine if BHV-7000 is Effective and Safe in Adults With Refractory Focal Onset Epilepsy | 2026-12 |
| NCT07505004Phase 3Praxis Precision MedicinesRandomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | 2027-01 |
| NCT06443463Biohaven Therapeutics Ltd.Long-term Safety and Tolerability of BHV-7000 | 2026-12 |
| NCT05673915Mayo ClinicStudy of Transcranial Direct Current Stimulation to Treat Epilepsy | 2026-12 |
| NCT05794295University of California, DavisSleep Architecture & Cognition in Focal Epilepsy | 2026-12-01 |
Add all 10 to your calendar (.ics) → With an account.
Among the 102 studies in Epilepsies, Partial with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The XEN1101 Phase 2 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the clinical efficacy, safety and tolerability of increasing doses of XEN1101 administered as adjunctive treatment in adult patients diagnosed with focal epilepsy, followed by an optional open-label extension (OLE).
The XEN1101 Phase 2 clinical trial is designed as a randomized, double-blind, placebo-controlled, multicenter study with an optional open-label extension (OLE) to evaluate the clinical efficacy, safety and tolerability of XEN1101 administered as adjunctive treatment in adult patients aged 18 to 75 years diagnosed with focal epilepsy. Approximately 300 patients will be randomized in a blinded manner to one of three active treatment groups or placebo in a 2:1:1:2 fashion (XEN1101 25 mg : 20 mg : 10 mg : Placebo). After screening, patients will have 8 weeks of baseline to assess frequency of seizures, followed by 8 weeks of treatment and a 6-week post treatment follow-up period. In order to be included in the study, patients must already be treated with a stable dose of 1 to 3 allowable current anti-epileptic drugs for at least one month prior to screening, during baseline, and throughout the double-blind portion (DBP) of the study. During the treatment period, patients will be given XEN1101 or placebo once daily in the evening. An OLE will be available to eligible patients who complete the DBP. All patients will receive a 20 mg daily dose of XEN1101 during this extension period.
The criteria were revised on the registry on Nov 5, 2026. See what changed
Key Inclusion Criteria:
Key Exclusion Criteria:
Any abnormalities on pre-study physical examination, vital signs, laboratory values or indicating a medical problem that would preclude study participation including but not limited to:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Capsule filled with 25 mg XEN1101
Drug: XEN1101
Capsule filled with 20 mg XEN1101
Drug: XEN1101
Capsule filled with 10 mg XEN1101
Drug: XEN1101
Placebo capsule
Drug: XEN1101
Oral dose
Median Percent Change in Focal Seizure Frequency
Median percent change in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo
Time frame: From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)
50% XEN1101 Response Rate
Responders are defined as patients experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline to DBP
Time frame: From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)
Percent Change in Focal Seizure Frequency Over Time
Percent change from baseline in focal seizure frequency at Month 1 and Month 2 in the DBP
Time frame: From baseline (8 weeks prior to Day 0) through to the final dose (up to Day 56)
| Milestone | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo |
|---|---|---|---|---|
| Started | 114 | 51 | 46 | 114 |
| Completed | 88 | 43 | 45 | 109 |
| Not completed | 26 | 8 | 1 | 5 |
Median percent change in monthly (28 days) focal seizure frequency from baseline to DBP for XEN1101 versus placebo
| Percent change | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo |
|---|---|---|---|---|
| Median Percent Change in Focal Seizure Frequency | -52.8 (-80.4 to -16.9) | -46.4 (-76.7 to -14.0) | -33.2 (-61.8 to 0.0) | -18.2 (-37.3 to 7.0) |
Responders are defined as patients experiencing ≥50% reduction in monthly (28 days) focal seizure frequency from baseline to DBP
| Participants | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo |
|---|---|---|---|---|
| 50% XEN1101 Response Rate | 61 | 22 | 13 | 17 |
Percent change from baseline in focal seizure frequency at Month 1 and Month 2 in the DBP
| Percent change from baseline | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo |
|---|---|---|---|---|
| Month 1 (Day 1 to 28) | -55.3 (-78.3 to -16.1) | -40.0 (-70.7 to -1.3) | -40.1 (-62.5 to -1.5) | -14.9 (-38.6 to 15.9) |
| Month 2 (Day 29 to Visit 8) | -64.7 (-91.1 to -32.8) | -52.2 (-81.1 to -33.7) | -30.3 (-56.9 to 0.3) | -21.8 (-45.6 to 4.9) |
Collected over 8 weeks. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 25 mg XEN1101 | 0/114 (0%) | 3/114 (2.6%) | 97/114 (85.1%) |
| 20 mg XEN1101 | 0/51 (0%) | 2/51 (3.9%) | 35/51 (68.6%) |
| 10 mg XEN1101 | 0/46 (0%) | 2/46 (4.3%) | 31/46 (67.4%) |
| Placebo | 0/114 (0%) | 3/114 (2.6%) | 56/114 (49.1%) |
| Event | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo |
|---|---|---|---|---|
| Confusional statePsychiatric disorders | 0/114 | 0/51 | 1/46 | 0/114 |
| SeizureNervous system disorders | 0/114 | 0/51 | 1/46 | 0/114 |
| HyponatremiaMetabolism and nutrition disorders | 0/114 | 0/51 | 1/46 | 0/114 |
| Psychotic disorderPsychiatric disorders | 0/114 | 1/51 | 0/46 | 0/114 |
| Somatic delusionPsychiatric disorders | 0/114 | 1/51 | 0/46 | 0/114 |
| Psychogenic seizurePsychiatric disorders | 1/114 | 0/51 | 0/46 | 0/114 |
| DizzinessNervous system disorders | 1/114 | 0/51 | 0/46 | 0/114 |
| Muscle spasticityNervous system disorders | 1/114 | 0/51 | 0/46 | 0/114 |
| Partial seizuresNervous system disorders | 0/114 | 0/51 | 0/46 | 1/114 |
| PresyncopeNervous system disorders | 0/114 | 0/51 | 0/46 | 1/114 |
| Event | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo |
|---|---|---|---|---|
| DizzinessNervous system disorders | 36/114 | 13/51 | 3/46 | 8/114 |
| SomnolenceNervous system disorders | 17/114 | 11/51 | 5/46 | 8/114 |
| HeadacheNervous system disorders | 9/114 | 6/51 | 6/46 | 9/114 |
| FatigueGeneral disorders | 14/114 | 4/51 | 5/46 | 6/114 |
| Balance disorderNervous system disorders | 13/114 | 4/51 | 2/46 | 2/114 |
| TremorNervous system disorders | 12/114 | 3/51 | 3/46 | 2/114 |
| AnxietyPsychiatric disorders | 2/114 | 5/51 | 0/46 | 6/114 |
| Urinary tract infectionInfections and infestations | 2/114 | 3/51 | 4/46 | 4/114 |
| AphasiaNervous system disorders | 8/114 | 1/51 | 1/46 | 1/114 |
| DysarthriaNervous system disorders | 8/114 | 0/51 | 1/46 | 0/114 |
| Age, Customized(years) | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo | Total |
|---|---|---|---|---|---|
| Age | 38.7 ± 13.1 | 41.7 ± 13.6 | 40.0 ± 12.1 | 42.9 ± 13.7 | 40.8 ± 13.3 |
| Sex: Female, Male(Participants) | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo | Total |
|---|---|---|---|---|---|
| Female | 54 | 26 | 27 | 61 | 168 |
| Male | 60 | 25 | 19 | 53 | 157 |
| Race/Ethnicity, Customized(Participants) | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo | Total |
|---|---|---|---|---|---|
| Asian | 1 | 0 | 1 | 2 | 4 |
| Black or African American | 2 | 1 | 2 | 7 | 12 |
| Native Hawaiian or Other | 1 | 1 | 0 | 1 | 3 |
| White or Caucasian | 105 | 49 | 42 | 102 | 298 |
| Other | 5 | 0 | 1 | 2 | 8 |
| Monthly seizure frequency in baseline(seizures/month (28 days)) | 25 mg XEN1101 | 20 mg XEN1101 | 10 mg XEN1101 | Placebo | Total |
|---|---|---|---|---|---|
| Median | 12.8 (8.4 to 24.6) | 14.5 (7.5 to 36.4) | 17.4 (8.0 to 55.6) | 13.4 (8.0 to 30.1) | 13.5 (7.9 to 30.3) |
PDFs hosted by the registry, ClinicalTrials.gov.
Ran from Jan 2019 to primary completion in Sep 2021, 31 months.
Results were first posted in Sep 2024, 3 years after primary completion. A results delay was requested in Aug 2022.
Completion moved once since we started tracking on Sep 25, 2026: Oct 2028 → Oct 2030, on Nov 5, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: XEN1101